Skip to main content

This website is intended for US healthcare professionals only.

INGREZZA® (valbenazine) capsules

Tardive dyskinesia impact and prevalence

Disruptive, distressing, stigmatizing—tardive dyskinesia (TD) has been shown to be an added burden for patients already managing an underlying mental illness1,2,a,b

Disruptivea,b

Uncontrolled movements can impact patients’ ability to perform daily activities1,2

Distressinga,b

Abnormal and uncontrolled movements may cause embarrassment in public1-3

Stigmatizinga,b

TD symptoms may exacerbate the stigma associated with existing mental illness1-4

a

Includes results based on a survey of patients diagnosed with TD (n=127), who were asked, “How would you rate your current ability to undertake your regular activities?” Responses based on a 3-point scale selection of “Low,” “Medium,” or “High”; “What would you say about your general well-being in each of the following areas?” Responses based on 7-point Likert scale (range of 1 [“Not good at all”] to 7 [“Excellent”]); “Tardive dyskinesia may impact you in different ways. To what extent has tardive dyskinesia impacted you in each of the following areas?” Responses based on 7-point Likert scale (range of 1 [“Not at all impacted”] to 7 [“Extremely impacted”]).1
b

Includes results based on a survey of psychiatric patients with a clinician-confirmed diagnosis of TD or absence of TD. Health-related quality of life was assessed by: SF-12 Health Survey, Version 2 (SF-12v2), Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF), Social Withdrawal subscale of the Internalized Stigma of Mental Illness Scale (SW-ISMI), and 2 questions on movement disorders.2

Between 7.2% and 30% of patients on antipsychotics had tardive dyskinesia according to a 2017 meta-analysis of 41 studies5:

30%

of patients on first-generation antipsychotics

20.7%

of patients on second-generation antipsychotics (with unspecified first-generation antipsychotic use)

7.2%

of patients on second-generation antipsychotics with no prior history of first-generation antipsychotics

While anyone with exposure to antipsychotics can develop TD,5 the following may be associated with increased risk:

Patient risk factors for TD

  • Aged 50 or older6
  • Substance use disorder7
  • Being postmenopausal8
  • Diagnosis of mood disorder9

Treatment risk factors for TD

  • Cumulative exposure to antipsychotics7
  • Treatment with anticholinergics7
  • History of acute drug-induced movement disorder7
  • Potency of antipsychotics10

Take the TD Challenge:
Overview and impact

What causes TD? What are the risk factors for TD?
How may TD impact your patients?
Put your knowledge to the test.

START TD CHALLENGE

EXPERT PERSPECTIVES:

The impact and importance of regular screening

Watch as Dr. Andrew Cutler discusses the challenges of TD and the importance of regular screening.

The impact and importance of regular screening, video

EXPERT PERSPECTIVES:

The impact and importance of regular screening

Watch as Dr. Andrew Cutler discusses the challenges of TD and the importance of regular screening.

REFERENCES:

  1. Data on file. Neurocrine Biosciences, Inc.
  2. McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28(12):3303-3312.
  3. Task Force on Tardive Dyskinesia. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
  4. Boumans CE, de Mooij KJ, Koch PA, van ’t Hof MA, Zitman FG. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull. 1994;20(2):339-344.
  5. Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-e278.
  6. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155(11):1521-1528.
  7. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33-43.
  8. Turrone P, Seeman MV, Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can J Psychiatry. 2000;45(3):288-290.
  9. Casey DE. Affective disorders and tardive dyskinesia. Encephale. 1988;14(spec):221-226.
  10. Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.

RECOGNIZE AND SCREEN FOR TD

Get familiar with the phenomenology of tardive dyskinesia and how to differentiate TD movements from other drug-induced movement disorders

VISIT TD MOVEMENTS

REVIEW EFFICACY IN TD

Explore how INGREZZA® (valbenazine) capsules reduced TD severity in both short- and long-term studies of adult patients with TD

VISIT EFFICACY IN TD

SEE REAL-WORLD RESULTS
WITH INGREZZA

View videos of real-world patients with TD treated with INGREZZA

WATCH CASE VIDEOS

REFERENCES:

  1. Data on file. Neurocrine Biosciences, Inc.
  2. McEvoy J, Gandhi SK, Rizio AA, et al. Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Qual Life Res. 2019;28(12):3303-3312.
  3. Task Force on Tardive Dyskinesia. Tardive Dyskinesia: A Task Force Report of the American Psychiatric Association. Washington, DC: American Psychiatric Association; 1992.
  4. Boumans CE, de Mooij KJ, Koch PA, van ’t Hof MA, Zitman FG. Is the social acceptability of psychiatric patients decreased by orofacial dyskinesia? Schizophr Bull. 1994;20(2):339-344.
  5. Carbon M, Hsieh C-H, Kane JM, Correll CU. Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017;78(3):e264-e278.
  6. Woerner MG, Alvir JM, Saltz BL, Lieberman JA, Kane JM. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry. 1998;155(11):1521-1528.
  7. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80(1):33-43.
  8. Turrone P, Seeman MV, Silvestri S. Estrogen receptor activation and tardive dyskinesia. Can J Psychiatry. 2000;45(3):288-290.
  9. Casey DE. Affective disorders and tardive dyskinesia. Encephale.1988;14(spec):221-226.
  10. Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.
+Expand-Collapse

Important Safety Information

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA, can increase the risk of depression and suicidal thoughts and

Important Information

INDICATION & USAGE

INGREZZA® (valbenazine) capsules and INGREZZA® SPRINKLE (valbenazine) capsules are indicated in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease.

IMPORTANT SAFETY INFORMATION

Depression and Suicidality in Patients with Huntington’s Disease: VMAT2 inhibitors, including INGREZZA and INGREZZA SPRINKLE, can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidal ideation, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidal ideation and behavior and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in patients with Huntington’s disease.